logo
  

Novavax, Serum File For Emergency Use Authorization Of COVID-19 Vaccine Candidate In South Africa

Novavax, Inc. (NVAX) and Serum Institute of India Pvt. Ltd. announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate. If authorized, the vaccine will be manufactured by and commercialized by Serum Institute in South Africa under the brand name Covovax.

Novavax' vaccine has received authorizations of the vaccine in over 170 countries. The company expects to submit a request for EUA for the vaccine in the U.S. after one month in accordance with guidance from the FDA regarding submission of all EUA vaccines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ryanair Holdings Plc reported Monday a loss in its fiscal year 2022, narrower than last year, with strong growth in traffic and load factor. Looking ahead, the company said it expects to return to reasonable profitability in fiscal 2023. Shares of the low fares airline were losing around 4 percent in the morning trading in Germany. The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert against Weis Markets' ready-to-eat or RTE General Tso Chicken meals due to misbranding and undeclared milk, a known allergen. The RTE General Tso Chicken meals were prepared, labeled and sold in the Deli area at Weis Markets stores between April 13 and May 11, 2022. Deutsche Telekom AG on Friday raised its fiscal 2022 adjusted earnings forecast after reporting significantly higher net profit in its first quarter. Shares of the German telecom major were gaining around 1 percent in the morning trading in Germany. For fiscal 2022, the company now expects to post adjusted EBITDA AL of more than 36.6 billion euros.
Follow RTT